5-benzyl-1-hydroxypyridin-2(1H)-one | 1160485-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-benzyl-1-hydroxypyridin-2(1H)-one
• 英文别名: 5-Benzyl-1-hydroxypyridin-2-one
• CAS: 1160485-49-3
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: YMBPJABOBPLYAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-溴-2-甲氧基吡啶 在 正丁基锂 、 palladium 10% on activated carbon 、 氢气 、 乙酰氯 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 氯仿 为溶剂， 反应 52.75h， 生成 5-benzyl-1-hydroxypyridin-2(1H)-one
  参考文献：
  名称：

  Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114443

文献信息

• Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
  作者：Zhen Liu、Yuan Yao、Mari Kogiso、Baisong Zheng、Lisheng Deng、Jihui J. Qiu、Shuo Dong、Hua Lv、James M. Gallo、Xiao-Nan Li、Yongcheng Song

  DOI：10.1021/jm500660f

  日期：2014.10.23

  total of 61 derivatives were synthesized, and their structure–activity relationships were investigated. Potent IDH1(R132H) inhibitors were identified with Ki values as low as 140 nM, while they possess weak or no activity against WT IDH1. Activities of selected compounds against IDH1(R132C) were found to be correlated with their inhibitory activities against IDH1(R132H), as well as cellular production

  异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症，例如神经胶质瘤。与野生型 (WT) IDH1 不同，突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG)，从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物，并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM，而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关，R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障，并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性（EC 50 = 0.26–1.8 μM）。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
  作者：Baisong Zheng、Yuan Yao、Zhen Liu、Lisheng Deng、Justin L. Anglin、Hong Jiang、B. V. Venkataram Prasad、Yongcheng Song

  DOI：10.1021/ml400036z

  日期：2013.6.13

  Mutations in isocitrate dehydrogenase (IDH), a key enzyme in the tricarboxylic acid cycle, have recently been found in similar to 75% glioma and similar to 20% acute myeloid leukemia. Different from the wild-type enzyme, mutant IDH1 catalyzes the reduction of alpha-ketoglutaric acid to D-2-hydroxyglutaric acid. Strong evidence has shown mutant IDH1 represents a novel target for this type of cancer. We found two 1-hydroxypyridin-2-one compounds that are potent inhibitors of R132H and R132C mutants with K-i values as low as 120 nM. These compounds exhibit >60-fold selectivity against wild-type IDH1 and can inhibit the production of D-2-hydroxyglutaric acid in IDH1 mutated cells, representing novel chemical Probes for cancer biology studies. We also report the first inhibitor-bound crystal structures of IDH1(R132H), showing these inhibitors have H-bond, electrostatic, and hydrophobic interactions with the mutant enzyme. Comparison with the substrate-bound IDH1 structures revealed the structural basis for the high enzyme selectivity of these compounds.